Armstrong Advisory Group’s SELLAS Life Sciences SLS Stock Holding History

Armstrong Advisory Group’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.61K	Buy	+380	New	+$2.62K	﹤0.01%	779

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Armstrong Advisory Group's SLS Position: Q2 2026 in Review

Armstrong Advisory Group opened a new position in SELLAS Life Sciences (SLS) in Q2 2026: 380 shares worth $5.61K. The stake represents ﹤0.01% of the portfolio and ranks #779 among its holdings.

193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

Armstrong Advisory Group held 380 shares of SELLAS Life Sciences worth $5.61K as of Q2 2026.
SELLAS Life Sciences was a new Armstrong Advisory Group position in Q2 2026.
SELLAS Life Sciences made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q2 2026, its #779 holding.
193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Armstrong Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.